Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
The Lancet, 07/10/2012
Clinical Article
DeJesus E et al. – If regulatory approval is given, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate would be the first integrase–inhibitor–based regimen given once daily and the only one formulated as a single tablet for initial HIV treatment.



